Bison

Bison Adverse Event Insights

The FDA Center for Veterinary Medicine database holds 10 adverse event reports for Bison, distributed across 2 distinct breeds currently tracked in the system. Of those reports, 6 involved a death outcome — producing a 6000.0% case-fatality rate among reported events, which reflects reporting severity bias rather than true population mortality. These figures are aggregated directly from openFDA's Animal & Veterinary Adverse Events endpoint and update as new voluntary submissions flow through pet owners, veterinarians, and drug manufacturers.

The most frequently reported clinical signs for Bison are Lack of efficacy - NOS (4 reports), Death (3 reports), Weakness (2 reports), INEFFECTIVE, PARASITE(S) NOS (2 reports), with Lack of efficacy - NOS leading the reaction traffic at 4 submissions. On the product side, Ivermectin is the single most-referenced drug with 3 reports, followed by Monensin Sodium (1), Doramectin (1), Doramectin; Phenol (1). This combination surfaces which therapeutic classes generate the most adverse event chatter for this species — a useful starting point when comparing Bison reporting patterns against other companion animals in the dataset.

Of the 15 Bison reports with a coded outcome, Died accounts for the largest share at 40.0%. Annual submission volume spans 2,011 to 2,022 reports across the 8 years on file, a range that reflects evolving owner awareness, veterinary reporting habits, and new product approvals rather than stable underlying incidence. The breed-level table below breaks these patterns down further, showing how the 2 tracked bison breeds compare on volume, deaths, and average age at report. As with all FDA adverse event data, correlation is the ceiling — causation requires clinical investigation beyond what these aggregates can provide.